For individuals battling Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the introduction of Vyndamax and Tafamidis meglumine represents a genuine breakthrough . These groundbreaking therapies preserve the transthyretin protein, preventing its damaging build-up and reduc